Epstein Secrets

ve and quantitative information about investment processes ■ Regular meetings with investors ■ Investments by partners and employees comprise 7% of Och-Ziff's AUMI ■ Och-Ziff's partners receive a substantial majority of their compensation from distributions tied to profitability As of September I. 2015 u

avid Windreich is Head of U.S. and European Investing for Och-Ziff and is a member of OZM's Board of Directors and Partner Management Committee. Mr. Windreich is also an Executive Managing Director. Prior to joining Och-Ziff at its inception in 1994, Mr. Windreich was a Vice President in the Equity Derivati

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

avid Windreich is Head of U.S. and European Investing for Och-Ziff and is a member of OZM's Board of Directors and Partner Management Committee. Mr. Windreich is also an Executive Managing Director. Prior to joining Och-Ziff at its inception in 1994, Mr. Windreich was a Vice President in the Equity Derivati

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

avid Windreich is Head of U.S. and European Investing for Och-Ziff and is a member of OZM's Board of Directors and Partner Management Committee. Mr. Windreich is also an Executive Managing Director. Prior to joining Och-Ziff at its inception in 1994, Mr. Windreich was a Vice President in the Equity Derivati